Investors of Merck & Co. (NYSE: MRK) and Moderna (Nasdaq: MRNA) were the most obvious—but not the only—beneficiaries when the companies announced what they said were the first-ever positive Phase III results for their mRNA-based cancer vaccine, the individualized neoantigen therapy (INT) intismeran autogene.
Merck and Moderna made ...